GlassScriptPhysician profile
Sareena Singh
NPI 1326205303
$53,572.22
in general payments reported to CMS, 2019-2025
31 companies · $4,168 in 2025
The $4,168 reported for 2025 was more than what 84% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $2,484 · 2021: $5,959 · 2022: $13K · 2023: $9,699 · 2024: $4,619 · 2025: $4,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Education: $3,015 · Travel and Lodging: $2,620 · Food and Beverage: $1,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,335.00 |
| Education | $3,014.79 |
| Travel and Lodging | $2,619.56 |
| Food and Beverage | $1,516.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $25,227.92 | 2019-2025 | Lynparza |
| Merck Sharp & Dohme LLC | $17,358.61 | 2019-2025 | Keytruda, Lynparza |
| Pfizer INC. | $4,447.66 | 2021-2025 | |
| Intuitive Surgical, INC. | $3,684.51 | 2024 | |
| Tesaro, INC. | $447.88 | 2019 | |
| Clovis Oncology, INC. | $280.66 | 2019-2022 | |
| Ethicon US, LLC | $266.06 | 2019-2025 | Dermabond, Surgiflo Hemostatic Matrix, Evarrest |
| Amgen INC. | $227.99 | 2019-2020 | |
| Abbvie INC. | $213.24 | 2019-2025 | |
| Eisai INC. | $197.31 | 2019-2025 | |
| Medtronic, INC. | $155.69 | 2022-2025 | Ligasure, Truclear |
| Bayer Healthcare Pharmaceuticals INC. | $127.82 | 2023 | |
| Glaxosmithkline, LLC. | $121.89 | 2020-2023 | Zejula, Jemperli |
| Heron Therapeutics, INC. | $103.08 | 2019 | |
| Kyowa Kirin, INC. | $92.63 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $84.70 | 2021-2022 | |
| Baxter Healthcare | $83.83 | 2025 | Tisseel |
| Tempus Ai, INC | $76.71 | 2025 | Xt Cdx |
| Genmab U.S., INC. | $57.89 | 2021-2024 | Tivdak |
| Foundation Medicine, INC. | $54.52 | 2020 | |
| Myovant Sciences INC. | $46.46 | 2021-2022 | |
| Integra Lifesciences Corporation | $37.36 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Mirati Therapeutics, INC. | $29.37 | 2023 | Krazati |
| Fennec Pharmaceuticals, INC. | $24.50 | 2025 | Fyarro |
| Helsinn Therapeutics (U.S.), INC. | $23.80 | 2019 | |
| Janssen Biotech, INC. | $22.66 | 2025 | Rybrevant |
| Jazz Pharmaceuticals INC. | $21.78 | 2022 | |
| Iovance Biotherapeutics, INC. | $21.17 | 2025 | Amtagvi |
| E.R. Squibb & Sons, L.L.C. | $19.01 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.51 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sareena Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.